| Prednidale Tablets (Prednisolone) | 
Prednidale 5 mg tablets are used to treat conditions characterised by inflammation or allergic reactions in cats and dogs. These conditions can show symptoms affecting the skin, gut, lungs and airways, locomotory system and the blood, hence Prednidale can be used to treat illnesses with wide ranging symptoms. Prednidale has extensive effects in the body which are of great benefit where used appropriately. Care needs to be taken to ensure that the condition being treated justifies steroid medication, to avoid unwanted side effects. In higher doses, Prednidale can be used to treat autoimmune problems and some forms of neoplasm. | | | | |
|  | Customers who purchased these items also purchased |   | | Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction 
Company name: Dechra Veterinary Products Limited
Address: (A business unit of Dechra Pharmaceuticals PLC)
Sansaw Business Park
Hadnall, Shrewsbury
Shropshire SY4 4AS
Telephone: 01939 211200
Fax: 01939 211201
Email: info@dechra-uk.com
Website: www.dechra.com
Presentation
White, circular, flat faced tablets with a breakline and PL5 imprinted on one face and CP or DP on the reverse. No data has been provided to demonstrate reproducible halving of the tablets.
Each tablet contains:
Active substance: Prednisolone 5 mg
Uses
Prednidale 5 mg tablets are indicated in the treatment of inflammatory and allergic diseases, including some autoimmune diseases and some neoplastic conditions in cats and dogs. Inflammatory, allergic and autoimmune processes may be involved in cutaneous, alimentary, respiratory, musculo-skeletal and haematological manifestations of disease.
Dosage and administration
Dose: 0.1-2.0 mg prednisolone per kg body weight per day. The tablets are divisible. The lowest effective dose must be used.
These tablets are not appropriate when dosing cats and small dogs at the lower recommended dosage rates and another tablet size may be required. The potential risks associated with these high dose levels should be assessed before commencing treatment.
Treatment should not be withdrawn suddenly. A gradual reduction of dosage is recommended.
Dogs should be dosed in the morning and cats should be dosed at night to coincide with the endogenous cortisol peak.
A single administration may be sufficient for some conditions such as anaphylaxis. Other conditions may require treatment for between one and three weeks at the above dosage levels. Dosage levels should be monitored carefully. Use the lowest effective dose. Alternate-day therapy should be implemented to control symptoms if possible, to minimise the risks of adrenal insufficiency.
For animals with tumours responsive to corticosteroid therapy, higher dose levels may be used based on the surface area of the animal. In some cases, dose levels of 20 mg per m2, reducing to 5 mg per m2, have been found useful. The potential risks associated with these high dose levels should be assessed before commencing treatment.
For oral administration only.
Contraindications, warnings, etc
Do not use in pregnant animals, those suffering from diabetes mellitus, in animals with renal insufficiency or those with corneal ulceration.
Do not use in animals being vaccinated with products containing live organisms. Treatment may render concurrent vaccination inoperative.
Appropriate therapy should be instituted in animals with concurrent bacterial infections. Use of corticosteroids may exacerbate viral infections.
Prolonged use at high dose levels may result in undesirable effects. Do not withdraw corticosteroid therapy suddenly.
Acute overdosage should be treated symptomatically. Serum electrolytes should be monitored. Consideration should be given to the use of antimicrobials due to the potential suppression of the immune system.
Corticosteroids, including prednisolone, have a wide range of effects. Polydipsia, polyuria and polyphagia may develop, particularly during the early stages of therapy. In the longer term, iatrogenic Cushing’s disease may develop.
Gastrointestinal ulceration has been reported in animals treated with corticosteroids. Steroids may cause enlargement of the liver (hepatomegaly) with increased serum hepatic enzymes.
Administration of single high doses are generally tolerated well, but medium to long term use may provoke reactions.
Corticosteroid therapy may lead to increased time in the healing of wounds and to a reduction in the ability of the body to resist infection. Appropriate anti-infective therapy may be required.
Pharmacologically active dose levels may lead to atrophy of the adrenal cortex, resulting in adrenal insufficiency. This may become apparent particularly after withdrawal of corticosteroid treatment. Adrenal insufficiency may be minimised by institution of alternate-day therapy, if practical. The dosage should be reduced and withdrawn gradually to avoid precipitation of adrenal insufficiency.
Corticosteroids are not recommended for use in pregnant animals. Studies in laboratory animals have shown that administration during early pregnancy may cause foetal abnormalities. Administration during the later stages of pregnancy may cause abortion or early parturition.
Insignificant amounts of prednisolone are generally eliminated in the milk of lactating animals, and therefore such use is not contraindicated.
Gastrointestinal ulceration may be exacerbated by corticosteroids in animals given non-steroidal anti-inflammatory drugs (NSAIDs).
Regular veterinary re-evaluation of animals on prolonged courses of prednisolone is recommended.
Special precautions to be taken by the person administering the veterinary medicinal product to animals: Gloves should be worn to administer the product and you should wash hands immediately after administration of the product.
General precautions: For animal treatment only.
Keep out of the reach and sight of children.
Pharmaceutical precautions
Do not store above 25°C. Store in a dry place. Store in tightly closed original container.
Disposal: Dispose of any unused product and empty containers in accordance with guidance from your local waste regulation authority.
Legal category
POM-V
Packaging quantities
Plastic pots containing 1000 tablets.
Further information
To be supplied only on veterinary prescription.
UK authorised veterinary medicinal product.
Marketing authorisation holder (if different from distributor)
Dechra Limited, Dechra House, Jamage Industrial Estate, Talke Pits, Stoke-on-Trent, Staffordshire, ST7 1XW.
Marketing authorisation number
Vm 10434/4009.
Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction
Company name: Dechra Veterinary Products Limited
Address: (A business unit of Dechra Pharmaceuticals PLC)
Sansaw Business Park
Hadnall, Shrewsbury
Shropshire SY4 4AS
Telephone: 01939 211200
Fax: 01939 211201
Email: info@dechra-uk.com
Website: www.dechra.com
Presentation
White, 11 mm circular tablets.
Each tablet contains:
Active substance: Prednisolone 25 mg
Uses
Prednidale 25 mg tablets are indicated in the treatment of inflammatory and allergic diseases, including some autoimmune diseases and some neoplastic conditions, in dogs. Inflammatory, allergic and autoimmune processes may be involved in cutaneous, alimentary, respiratory, musculo-skeletal and haematological manifestations of disease.
Dosage and administration
Dose: 0.1-2.0 mg prednisolone per kg body weight per day. The lowest effective dose must be used.
These tablets are not appropriate when dosing small dogs at the lower recommended dosage rates and the 5 mg tablet size may be required.
Treatment should not be withdrawn suddenly. A gradual reduction of dosage is recommended.
Dogs should be dosed in the morning to coincide with the endogenous cortisol peak.
A single administration may be sufficient for some conditions such as anaphylaxis. For more general treatment, administration for between one and three weeks at the above dosage levels may be required. Dosage levels should be monitored carefully to ensure that the lowest effective dose is used. Alternate-day therapy should be implemented to control symptoms if possible, to minimise the risks of adrenal insufficiency.
For animals with tumours responsive to corticosteroid therapy, higher dose levels may be used based on the surface area of the animal. In some cases, dose levels of 20 mg per m2, reducing to 5 mg per m2, have been found useful. The potential risks associated with these high dose levels should be assessed before commencing treatment.
For oral administration in dogs.
Contraindications, warnings, etc
Do not use in pregnant animals, those suffering from diabetes mellitus, in animals with renal insufficiency or those with corneal ulceration.
Do not use in animals being vaccinated with products containing live organisms. Treatment may render concurrent vaccination inoperative.
Appropriate therapy should be instituted in animals with concurrent bacterial infections. Use of corticosteroids may exacerbate viral infections.
Prolonged use at high dose levels may result in undesirable effects. Do not withdraw corticosteroid therapy suddenly.
Signs of overdosage should be treated symptomatically. Serum electrolytes should be monitored. Consideration should be given to the use of antimicrobials due to the potential suppression of the immune system.
Corticosteroids, including prednisolone, have a wide range of effects. Polydipsia, polyuria and polyphagia may develop, particularly during the early stages of therapy. In the longer term, iatrogenic Cushing’s disease may develop.
Gastrointestinal ulceration has been reported in animals treated with corticosteroids. Steroids may cause enlargement of the liver (hepatomegaly) with increased serum hepatic enzymes.
Administration of single high doses are generally tolerated well, but medium to long term use may provoke reactions.
Corticosteroid therapy may lead to increased time in the healing of wounds and to a reduction in the ability of the body to resist infection. Appropriate anti-infective therapy may be required.
Pharmacologically active dose levels may lead to atrophy of the adrenal cortex, resulting in adrenal insufficiency. This may become apparent particularly after withdrawal of corticosteroid treatment. Adrenal insufficiency may be minimised by institution of alternate-day therapy, if practical. The dosage should be reduced and withdrawn gradually to avoid precipitation of adrenal insufficiency.
Corticosteroids are not recommended for use in pregnant animals. Studies in laboratory animals have shown that administration during early pregnancy may cause foetal abnormalities. Administration during the later stages of pregnancy may cause abortion or early parturition.
Insignificant amounts of prednisolone are generally eliminated in the milk of lactating animals, and therefore such use is not contraindicated.
Gastrointestinal ulceration may be exacerbated by corticosteroids in animals given non-steroidal anti-inflammatory drugs (NSAIDs).
Regular veterinary re-evaluation of animals on prolonged courses of prednisolone is recommended.
Special precautions to be taken by the person administering the veterinary medicinal product to animals: In the event of accidental ingestion, particularly by a child, seek medical advice and show the doctor the label or the package insert.
Gloves should be worn to administer the product and you should wash hands immediately after administration of the product.
General precautions: For animal treatment only.
Keep out of the reach and sight of children.
Pharmaceutical precautions
Do not store above 25°C. Store in tightly closed original container. Store in a dry place.
Disposal: Dispose of any unused product and empty containers in accordance with guidance from your local waste regulation authority.
Legal category
POM-V
Packaging quantities
100 tablets per container.
Further information
To be supplied only on veterinary prescription.
UK authorised veterinary medicinal product.
Marketing authorisation holder (if different from distributor)
Dechra Limited, Dechra House, Jamage Industrial Estate, Talke Pits, Stoke-on-Trent, Staffordshire, ST7 1XW.
Marketing authorisation number
Vm 10434/4008.
|
